Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLO: Dolutegravir PK in Severe Hepatic Impairment
NCT03813979Phase 4Withdrawn
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Area Under the Curve at 24 hours. Planned start Nov 2020; status: withdrawn.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03813979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03813979.